Drug Profile

QEL 005

Alternative Names: QEL-005

Latest Information Update: 29 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quell Therapeutics
Class Anti-inflammatories; Antirheumatics; CAR-T cell therapies; Gene therapies; Immunotherapies; Skin disorder therapies
Mechanism of Action Immunologic cytotoxicity; Regulatory T-lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Oct 2025 Quell Therapeutics intends to file CTA applications for QEL 005 before 4Q 2025
25 Oct 2025 Quell Therapeutics intends to initiate the phase I/II CHILL trial in 1H 2026
16 Oct 2025 Early research in Autoimmune disorders in United Kingdom (Parenteral) (Quell Therapeutics pipeline, October 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com